ARIAD Pharmaceuticals, Inc.s in-depth stock price analysis indicates that the stock price has rallied 69.63% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 132.68% . Looking at the past 52 week period, the stock price is up at 405.3% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of ARIAD Pharmaceuticals, Inc. has a positive value of 94.68 compared to overall market. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) has climbed 0.21% in the past week and advanced 0.68% in the last 4 weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.6%. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) has underperformed the index by 1.13% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.04 points or 0.17% at $23.85 with 3,241,849 shares getting traded. Post opening the session at $23.86, the shares hit an intraday low of $23.85 and an intraday high of $23.89 and the price was in this range throughout the day. The company has a market cap of $4,632 million and the number of outstanding shares has been calculated to be 194,200,860 shares. The 52-week high of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is $23.89 and the 52-week low is $4.37.
Ariad Pharmaceuticals Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $-0.18. The company had revenue of $46.02 million for the quarter, compared to analysts expectations of $42.80 million. The companys revenue was up 58.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.29 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Ariad Pharmaceuticals was Downgraded by SunTrust to Hold on Jan 11, 2017. Ariad Pharmaceuticals was Downgraded by Jefferies to Hold on Jan 10, 2017. Company shares were Upgraded by Barclays on Jan 10, 2017 to Equal Weight, Raises Price Target to $ 24 from a previous price target of $9 .Ariad Pharmaceuticals was Downgraded by Leerink Partners to Mkt Perform on Jan 10, 2017.
Company has reported several Insider transactions to the SEC, on Jan 10, 2017, Daniel M Bollag (Sr. VP, Reg. Affairs & Quality) sold 32,000 shares at 23.78 per share price.On Sep 28, 2016, Timothy P Clackson (President, R&D, CSO) sold 8,750 shares at 13.98 per share price.On Jun 29, 2016, Hugh M Cole (SVP, Chief Business Officer) sold 6,012 shares at 7.05 per share price.
Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.